Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-09-02Clinical Trial Update: HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMM [Phase 2]
This clinical trial update describes a Phase 2 study of selinexor in combination with a bispecific antibody (HCMT/MM2401) for relapsed/refra…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events
A completed Stanford-led clinical trial evaluating wearable sensors and molecular omics approaches to detect and mitigate adverse events dur…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE) [Phase 2]
A Phase 2 trial (ROTATE) evaluating talquetamab and teclistamab in newly diagnosed multiple myeloma is currently recruiting, aiming to engag…
-
CLINICAL_TRIALS research · 2025-08-29Clinical Trial Update: Factors Associated With Health-related Quality of Life and Social Participation of Patients With Multiple Myeloma and Their Caregivers
Clinical trial is currently recruiting to investigate factors associated with health-related quality of life and social participation in pat…
-
CLINICAL_TRIALS research · 2025-08-26Clinical Trial Update: Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors [NA]
A Barbara Ann Karmanos Cancer Institute study aims to address social determinants of health among cancer survivors in Metro Detroit and is c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma [Phase 2]
A Phase 2 trial is evaluating the combination of talquetamab and lenalidomide as maintenance therapy after stem cell transplant in multiple …
-
CLINICAL_TRIALS research · 2025-08-24Clinical Trial Update: A Phase I Trial to Establish the Safety and Maximum Tolerated Dose of High-affinity Autologous BCMA-targeting Chimeric Antigen Receptor (CAR) T-cells in Patients With Relapsed and Refractory B-cell Malignancies [Phase 1]
Phase I study to establish safety and maximum tolerated dose of autologous BCMA-targeting CAR T-cells in relapsed/refractory diffuse large B…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure [Phase 2]
Phase 2 trial comparing daratumumab, bortezomib, and dexamethasone versus cyclophosphamide, bortezomib, and dexamethasone in newly diagnosed…
-
CLINICAL_TRIALS research · 2025-08-22Clinical Trial Update: Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.
This clinical trial update discusses patient perspectives on home-based, subcutaneous Velcade (bortezomib) for multiple myeloma.
-
CLINICAL_TRIALS research · 2025-08-21Clinical Trial Update: Home Treatment With Carfilzomib in Patients With Multiple Myeloma
A clinical trial update describes home-based treatment with carfilzomib for patients with multiple myeloma, currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-19Clinical Trial Update: Study of ODX (OsteoDex) in Multiple Myeloma [Phase 1, Phase 2]
Clinical trial update for ODX (OsteoDex) in multiple myeloma, a Phase 1/2 study currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease [Phase 2]
A Phase 2 clinical trial evaluating the SVRd regimen for newly diagnosed multiple myeloma with extramedullary disease is currently recruitin…
-
CLINICAL_TRIALS research · 2025-08-17Clinical Trial Update: Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program [NA]
This is a clinical trial update for a screening and patient navigation program aimed at early detection of multiple myeloma and related diso…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma [Phase 1]
This Phase 1 trial evaluates YTS104 cell injections for relapsed or refractory multiple myeloma and is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating an anti-CD38 antibody-drug conjugate for relapsed or refractory multiple myeloma is currently recruiti…
-
CLINICAL_TRIALS research · 2025-08-15Clinical Trial Update: Chaplain-Delivered Compassion Meditation to Improve Spiritual Care of Patients Receiving Stem Cell Transplantation [NA]
This clinical trial update covers an ongoing study evaluating chaplain-delivered compassion meditation to improve spiritual care for patient…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating venetoclax with daratumumab and dexamethasone, with or without bortezomib, in relapsed or refractory multi…
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: IMMUNOPLANT for Newly Diagnosed Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating IMMUNOPLANT for newly diagnosed multiple myeloma is currently recruiting.
-
CLINICAL_TRIALS research · 2025-08-14Clinical Trial Update: A Study of Real Life Treatment for Multiple Myeloma (MM)
A real-life treatment study for multiple myeloma sponsored by Takeda is listed as active but not recruiting.
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: RN1201 Injection in Newly Diagnosed High-Risk Cytogenetic Multiple Myeloma [Phase 1]
Phase 1 trial of RN1201 Injection in newly diagnosed high-risk cytogenetic multiple myeloma patients who are ineligible or unwilling to unde…
-
CLINICAL_TRIALS research · 2025-08-11Clinical Trial Update: Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara [Phase 2]
Phase 2 trial update comparing Daratumumab-bortezomib-dexamethasone (Dara-VCd) against bortezomib-thalidomide-dexamethasone (VTd), followed …
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: A Study to Assess Adverse Events and Change in Disease State of Intravenously (IV) Infused Etentamig (ABBV-383) of Adult Participants With Relapsed or Refractory Multiple Myeloma in Japan [Phase 1]
This Phase 1 clinical trial update describes ABBV-383 (Etentamig) being studied in adults with relapsed/refractory multiple myeloma in Japan…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: A Trial for Relapsed and Relapsed/Refractory Multiple Myeloma Patients [Phase 2]
Phase 2 clinical trial update for relapsed and relapsed/refractory multiple myeloma patients, currently active but not recruiting.
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma [Phase 2]
A Phase 2 clinical trial update describing a steroid-sparing treatment approach for newly diagnosed transplant-ineligible patients with mult…
-
CLINICAL_TRIALS research · 2025-08-08Clinical Trial Update: GMMG Multiple Myeloma Registry
The document is an update on the GMMG Multiple Myeloma Registry, a recruiting observational study intended to collect data on patients with …